SCHEMBL20028

SCHEMBL20028

CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]2(C)CC[C@@]2(C)[C@@H]3C[C@@H](C)CC[C@]3(C)CC[C@]12C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.69
CCR6 P51684 1/20 0.69
PAX8 Q06710 1/20 0.69
TLR9 Q9NR96 1/20 0.69
NR4A1 P22736 7/20 0.68
PTPN1 P18031 1/20 0.67
CASP1 P29466 1/20 0.67
ABHD6 Q9BV23 1/20 0.67
KDM4E B2RXH2 1/20 0.67
TP53 P04637 1/20 0.67
CYP3A4 P08684 1/20 0.67
MAPT P10636 1/20 0.67
HPGD P15428 1/20 0.67
ALOX15 P16050 1/20 0.67
ALOX12 P18054 1/20 0.67
MAPK1 P28482 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
TERT O14746 6/20 0.66
HSP90AB1 P08238 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29475985 1.00 HSP90AA1 (0.69) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL22822432 0.89 HSP90AA1 (0.54) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL14682178 0.88 HSP90AA1 (0.71) HSP90AA1CCR6PAX8TLR9NR4A1
Isoiguesterol SCHEMBL30271471 0.88 HSP90AA1 (0.66) HSP90AA1CCR6PAX8TLR9NR4A1
Tingenone SCHEMBL17064 0.86 HSP90AA1 (0.66) HSP90AA1CCR6PAX8TLR9NR4A1
Tingenone SCHEMBL20980043 0.86 HSP90AA1 (0.66) HSP90AA1CCR6PAX8TLR9NR4A1
Tingenone SCHEMBL20957664 0.86 HSP90AA1 (0.66) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL18781832 0.85 HSP90AA1 (0.79) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL17328989 0.85 HSP90AA1 (0.79) HSP90AA1CCR6PAX8TLR9NR4A1
SCHEMBL30688055 0.85 HSP90AA1 (0.67) HSP90AA1CCR6PAX8TLR9NR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753436-B2 Analogs of celastrol ERX PHARMACEUTICALS CORPORATION (US) 2023-09-12 US disclosed
US-11753436-B2 Analogs of celastrol ERX PHARMACEUTICALS CORPORATION (US) 2023-09-12 US disclosed
WO-2021047672-A1 TRITERPENOID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING NUCLEAR RECEPTOR SUBFAMILY 4 GROUP MEMBER 1-MEDIATED DISEASE IXMEDICINE CO., LTD (CN) 2021-03-18 WO disclosed
US-20210061851-A1 ANALOGS OF CELASTROL ERX PHARMACEUTICALS CORPORATION 2021-03-04 US disclosed
WO-2020253814-A1 TRIPTERINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF 中国科学院上海药物研究所 2020-12-24 WO disclosed
US-10662218-B2 Analogs of celastrol ERX PHARMACEUTICALS CORPORATION 2020-05-26 US disclosed
WO-2019158359-A1 COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2019-08-22 WO disclosed
WO-2017070615-A1 ANALOGS OF CELASTROL ERX PHARMACEUTICALS, INC. (US) 2017-04-27 WO disclosed
WO-2012024893-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS SUZHOU NEUPHARMA CO., LTD. (CN) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061851-A1 ANALOGS OF CELASTROL GIPR, GPR119, EBP HSP90AA1 123/4885CCR6 3242/4885PAX8 965/4885
US-10662218-B2 Analogs of celastrol GIPR, GPR119, EBP HSP90AA1 123/4885CCR6 3242/4885PAX8 965/4885
US-11753436-B2 Analogs of celastrol GIPR, GPR119, EBP HSP90AA1 123/4885CCR6 3242/4885PAX8 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.